Hewang Pharmaceutical (00013) is now up more than 4%. As of press release, it has risen 4.4% to HK$27.3, with a turnover of HK$30.6461 million.
The Zhitong Finance App learned that Hewang Pharmaceutical (00013) is now up more than 4%. As of press release, it has risen 4.4% to HK$27.3, with a turnover of HK$30.6461 million.
According to the news, Hutchison Pharmaceutical recently announced that it has begun the registration phase of a phase II/III study of solepinib in the treatment of adult patients with warm-antibody autoimmune hemolytic anemia (waIHa) in China. Prior to that, the Phase II proof-of-concept phase of the study had positive data and communication with China's National Drug Administration. If the results of the study are positive, the data is expected to be used to support the submission of new drug marketing applications in the future.
CITIC Construction Investment previously released a research report saying that Hutchison Pharmaceuticals announced the full year results of 2023. Revenue from the oncology/immunization comprehensive business was in line with the previous company's target of 45—55 million US dollars. Product sales increased 28% year over year. Among them, furoquintinib was listed in the US in November 23, with revenue reaching 15 million US dollars in 23. At the same time, it is expected that it will be approved in Europe and Japan and further expanded overseas this year. By the end of 2024, AstraZeneca is expected to submit an indication of sevotinib for refractory non-small cell lung cancer with abnormal MET, and the internationalization process is progressing further.